Targeting the heart-liver cross-talk and the mediating IL-6/STAT3/MR/FGF21 signaling axis may provide novel strategies to improve cardiac repair after MI and ultimately the treatment for HF. This evidence concerns the gene STAT3 and myocardial infarction.